Glycyrrhizic acid, Phospholipids | Phosphogliv capsules 50 pcs.
Special Price
$23.28
Regular Price
$31.00
In stock
SKU
BID462902
Release form
Hard gelatin capsules No. 0, capsule body - orange, lid - black.
The contents of the capsule is a granular powder from white with a slightly yellowish tint to light yellow in color, with a faint specific smell.
For 30, 50, 100, 200 or 300 capsules in plastic containers with lids made of high pressure polyethylene or propylene.
Hard gelatin capsules No. 0, capsule body - orange, lid - black.
The contents of the capsule is a granular powder from white with a slightly yellowish tint to light yellow in color, with a faint specific smell.
For 30, 50, 100, 200 or 300 capsules in plastic containers with lids made of high pressure polyethylene or propylene.
Release form
Hard gelatin capsules No. 0, capsule body - orange, lid - black.
The contents of the capsule is a granular powder from white with a slightly yellowish tint to light yellow in color, with a faint specific smell.
For 30, 50, 100, 200 or 300 capsules in plastic containers with lids made of high pressure polyethylene or propylene.
Packing
50 pcs.
Pharmacological action
Combined agent. It has a membrane stabilizing, hepatoprotective and antiviral effect.
Phosphatidylcholine (the active substance of phospholipids) is the main structural element of cell and intracellular membranes, is able to restore their structure and function in case of damage, having a cytoprotective effect. It normalizes protein and lipid metabolism, prevents the loss of enzymes and other active substances by hepatocytes, restores the detoxifying function of the liver, and inhibits the formation of connective tissue, reducing the risk of liver fibrosis and cirrhosis.
Glycyrrhizic acid has an anti-inflammatory effect, inhibits the reproduction of viruses in the liver and other organs by stimulating the production of interferons, increasing phagocytosis, increased activity of natural killer cells. It has a hepatoprotective effect due to antioxidant and membrane stabilizing activity. It potentiates the action of endogenous glucocorticosteroids, providing an anti-inflammatory and anti-allergic effect in non-infectious liver lesions.
In case of skin lesions due to the membrane-stabilizing and anti-inflammatory action of the components, it limits the spread of the process and contributes to the regression of the disease.
Pharmacokinetics.
Phosphatidylcholine
More than 90% of the orally administered phospholipids are absorbed in the small intestine. Most of them are cleaved by phospholipase A to 1-acetyl-lysophosphatidylcholine, 50% of which undergoes reverse acetylation to polyunsaturated phosphatidylcholine during absorption in the intestinal mucosa. The polyunsaturated
phosphatidylcholine with lymph flow enters the bloodstream, from where it mainly enters the liver in the form associated with high density lipoproteins. The pharmacokinetics in humans has been studied using dilenoleyl phosphatidylcholine with a radioactive label of 3H (choline part) and 14C (linoleic acid residue). The maximum concentration of 3H is reached after 6-24 hours, accounting for 19.9% of the prescribed dose of 14C - after 4-12 hours, amounting to 27.9%. The half-life of the choline component is 66 hours, the linoleic acid residue is 32 hours. In feces, 2% 3H and 4.5% - 14 C in urine are found - 6% 3H and a minimum amount of 14C. Both isotopes are absorbed in the intestine by more than 90%.
Glycyrrhizic acid
After oral administration in the intestine under the influence of the enzyme -glucuronidase, produced by the bacteria of normal microflora, an active metabolite is formed from glycyrrhizic acid - β-glycyrrhetic acid, which is absorbed into the systemic circulation. In the blood, β-glycyrrhetic acid binds to albumin and is almost completely transported to the liver. Isolation of -Glycyrrhetic acid occurs predominantly with bile, in residual quantities with urine.
According to experimental data, phospholipids improve the lipophilic properties of glycyrrhizic acid, increasing its intensity and absorption rate by more than 2 times.
Indications
- Fatty liver degeneration (hepatosis), alcoholic, toxic, including medicinal, liver damage
- As part of the complex treatment of viral hepatitis (acute and chronic), cirrhosis and psoriasis.
Contraindications
Hypersensitivity to glycyrrhizic acid, phosphatidylcholine or other components of the drug
Antiphospholipid syndrome
Pregnancy (data on efficacy and safety are not enough)
Breastfeeding period (data on efficacy and safety are not enough)
Children under 12 years of age (data on efficacy and safety are not enough).
Use during pregnancy and lactation
The drug is contraindicated in pregnancy and lactation.
Special instructions
Caution:
In patients with portal hypertension. In patients with arterial hypertension.
In the presence of these diseases, before taking the drug, you must consult your doctor.
In case of high blood pressure, stop taking the drug and consult a doctor.
The drug does not adversely affect the ability to drive vehicles and perform other work that requires an increased concentration of attention and speed of psychomotor reactions.
Composition
Active substances:
Phospholipids (Lipoid C 80) (in terms of 100% substance) (the main component phosphatidylcholine 73-79%) - 65 mg,
sodium glycyrrhizinate (trisodium glycyrrhizic acid) - 35 mg.
Excipients:
microcrystalline cellulose - 141.2 mg,
calcium carbonate - 204.7 mg,
calcium stearate - 0.9 mg,
talc - 7.7 mg,
silica colloidal dioxide (aerosil) - 5.5 mg,
hard gelatin capsules - 96.0 mg [case: sunset sunset dye yellow (E110) - 1.0%, titanium dioxide (E171) - 1.0%, gelatin - up to 100.0% cap: titanium dioxide ( E171) - 0.2%, iron oxide black oxide (E172) - 3.5%, gelatin - up to 100.0%].
Dosage and administration
Take orally, with food, without chewing, with a small amount of liquid.
Recommended dosing regimen for adults and children over 12 years of age - 2 capsules 3 times a day.
Duration of use can be up to 6 months, on average - 3 months.
Side effects
Allergic reactions: skin rash, difficulty in nasal breathing, conjunctivitis, cough.
From the cardiovascular system: transient (transient) increase in blood pressure, peripheral edema.
If you experience these symptoms, you should stop taking the drug and consult your doctor.
Drug interaction
Not described
Overdose
No overdose of Phosphogliv® has been reported at this time.
Storage Conditions
Do not store above 25 РC. Keep out of reach of children.
Shelf life
3 years.
Terms and conditions
without prescription
Dosage form
capsules
Possible product names
PHOSFOGLIV N50 CAPS
Phosphogliv caps N50 (pack control N10x5) ind pack
Phosphogliv caps N50 *
PHOSFOGLIV CAPS. 65MG + 35MG No. 50
PHOSFOGLIV CAPS. N50
Pharmstandard-Leksredstva, Russia
Hard gelatin capsules No. 0, capsule body - orange, lid - black.
The contents of the capsule is a granular powder from white with a slightly yellowish tint to light yellow in color, with a faint specific smell.
For 30, 50, 100, 200 or 300 capsules in plastic containers with lids made of high pressure polyethylene or propylene.
Packing
50 pcs.
Pharmacological action
Combined agent. It has a membrane stabilizing, hepatoprotective and antiviral effect.
Phosphatidylcholine (the active substance of phospholipids) is the main structural element of cell and intracellular membranes, is able to restore their structure and function in case of damage, having a cytoprotective effect. It normalizes protein and lipid metabolism, prevents the loss of enzymes and other active substances by hepatocytes, restores the detoxifying function of the liver, and inhibits the formation of connective tissue, reducing the risk of liver fibrosis and cirrhosis.
Glycyrrhizic acid has an anti-inflammatory effect, inhibits the reproduction of viruses in the liver and other organs by stimulating the production of interferons, increasing phagocytosis, increased activity of natural killer cells. It has a hepatoprotective effect due to antioxidant and membrane stabilizing activity. It potentiates the action of endogenous glucocorticosteroids, providing an anti-inflammatory and anti-allergic effect in non-infectious liver lesions.
In case of skin lesions due to the membrane-stabilizing and anti-inflammatory action of the components, it limits the spread of the process and contributes to the regression of the disease.
Pharmacokinetics.
Phosphatidylcholine
More than 90% of the orally administered phospholipids are absorbed in the small intestine. Most of them are cleaved by phospholipase A to 1-acetyl-lysophosphatidylcholine, 50% of which undergoes reverse acetylation to polyunsaturated phosphatidylcholine during absorption in the intestinal mucosa. The polyunsaturated
phosphatidylcholine with lymph flow enters the bloodstream, from where it mainly enters the liver in the form associated with high density lipoproteins. The pharmacokinetics in humans has been studied using dilenoleyl phosphatidylcholine with a radioactive label of 3H (choline part) and 14C (linoleic acid residue). The maximum concentration of 3H is reached after 6-24 hours, accounting for 19.9% of the prescribed dose of 14C - after 4-12 hours, amounting to 27.9%. The half-life of the choline component is 66 hours, the linoleic acid residue is 32 hours. In feces, 2% 3H and 4.5% - 14 C in urine are found - 6% 3H and a minimum amount of 14C. Both isotopes are absorbed in the intestine by more than 90%.
Glycyrrhizic acid
After oral administration in the intestine under the influence of the enzyme -glucuronidase, produced by the bacteria of normal microflora, an active metabolite is formed from glycyrrhizic acid - β-glycyrrhetic acid, which is absorbed into the systemic circulation. In the blood, β-glycyrrhetic acid binds to albumin and is almost completely transported to the liver. Isolation of -Glycyrrhetic acid occurs predominantly with bile, in residual quantities with urine.
According to experimental data, phospholipids improve the lipophilic properties of glycyrrhizic acid, increasing its intensity and absorption rate by more than 2 times.
Indications
- Fatty liver degeneration (hepatosis), alcoholic, toxic, including medicinal, liver damage
- As part of the complex treatment of viral hepatitis (acute and chronic), cirrhosis and psoriasis.
Contraindications
Hypersensitivity to glycyrrhizic acid, phosphatidylcholine or other components of the drug
Antiphospholipid syndrome
Pregnancy (data on efficacy and safety are not enough)
Breastfeeding period (data on efficacy and safety are not enough)
Children under 12 years of age (data on efficacy and safety are not enough).
Use during pregnancy and lactation
The drug is contraindicated in pregnancy and lactation.
Special instructions
Caution:
In patients with portal hypertension. In patients with arterial hypertension.
In the presence of these diseases, before taking the drug, you must consult your doctor.
In case of high blood pressure, stop taking the drug and consult a doctor.
The drug does not adversely affect the ability to drive vehicles and perform other work that requires an increased concentration of attention and speed of psychomotor reactions.
Composition
Active substances:
Phospholipids (Lipoid C 80) (in terms of 100% substance) (the main component phosphatidylcholine 73-79%) - 65 mg,
sodium glycyrrhizinate (trisodium glycyrrhizic acid) - 35 mg.
Excipients:
microcrystalline cellulose - 141.2 mg,
calcium carbonate - 204.7 mg,
calcium stearate - 0.9 mg,
talc - 7.7 mg,
silica colloidal dioxide (aerosil) - 5.5 mg,
hard gelatin capsules - 96.0 mg [case: sunset sunset dye yellow (E110) - 1.0%, titanium dioxide (E171) - 1.0%, gelatin - up to 100.0% cap: titanium dioxide ( E171) - 0.2%, iron oxide black oxide (E172) - 3.5%, gelatin - up to 100.0%].
Dosage and administration
Take orally, with food, without chewing, with a small amount of liquid.
Recommended dosing regimen for adults and children over 12 years of age - 2 capsules 3 times a day.
Duration of use can be up to 6 months, on average - 3 months.
Side effects
Allergic reactions: skin rash, difficulty in nasal breathing, conjunctivitis, cough.
From the cardiovascular system: transient (transient) increase in blood pressure, peripheral edema.
If you experience these symptoms, you should stop taking the drug and consult your doctor.
Drug interaction
Not described
Overdose
No overdose of Phosphogliv® has been reported at this time.
Storage Conditions
Do not store above 25 РC. Keep out of reach of children.
Shelf life
3 years.
Terms and conditions
without prescription
Dosage form
capsules
Possible product names
PHOSFOGLIV N50 CAPS
Phosphogliv caps N50 (pack control N10x5) ind pack
Phosphogliv caps N50 *
PHOSFOGLIV CAPS. 65MG + 35MG No. 50
PHOSFOGLIV CAPS. N50
Pharmstandard-Leksredstva, Russia
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review